Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities

In light of the disappointing termination of clinical trials with potent complex I inhibitors, such as IACS-010759, justification for oxidative phosphorylation inhibitors and mitochondrial targeting strategies has been called into question. Consideration of these agents’ potency, tissue selectivity...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of cancer Jg. 129; H. 6; S. 897 - 899
Hauptverfasser: Machado, Nicole D, Heather, Lisa C, Harris, Adrian L, Higgins, Geoff S
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England Nature Publishing Group 05.10.2023
Schlagworte:
Clinical trials
Electron transport chain
Humans
Inhibitor drugs
Medical research
Mitochondria - metabolism
Oxidative Phosphorylation
Phosphorylation
Targeted cancer therapy
Toxicity
ISSN:0007-0920, 1532-1827, 1532-1827
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In light of the disappointing termination of clinical trials with potent complex I inhibitors, such as IACS-010759, justification for oxidative phosphorylation inhibitors and mitochondrial targeting strategies has been called into question. Consideration of these agents’ potency, tissue selectivity and toxicity demonstrate what lessons can be learned from this failure and where new opportunities lie.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0007-0920
1532-1827
1532-1827
DOI:10.1038/s41416-023-02394-9